Why the study?
Data on obesity as an independent cardiovascular risk modifier in metabolically healthy individuals are limited, particularly among patients with CAD.
Does metabolic status predict MACE, all-cause mortality, and revascularization in patients evaluated for chronic coronary syndrome?
Does metabolic status predict MACE, all-cause mortality, and revascularization in patients evaluated for chronic coronary syndrome?
Metabolic health, rather than obesity, is a key predictor of adverse events in chronic coronary syndrome, suggesting cardiovascular risk assessment should prioritize metabolic health over BMI.
Answers are grounded in this paper and cite their sources.
Metabolically healthy obesity conferred no excess risk in CCS; hypothesis-generating for prioritizing metabolic over BMI-based risk assessment.
AIMS: Metabolic disorders are established risk factors for coronary artery disease (CAD) and major adverse cardiovascular events (MACEs). Although obesity is closely associated with metabolic disease, data on its role as a separate cardiovascular risk modifier in metabolically healthy (MH) individuals are limited, particularly in patients with CAD. Thus, this study aims to investigate risk profiles of metabolic phenotypes on outcomes in patients undergoing invasive coronary angiography. METHODS AND RESULTS: A total of 12 760 patients evaluated for chronic coronary syndrome (CCS) were distinguished into four metabolic phenotypes: MH/metabolically unhealthy (MU) non-obese/obese (MHN, MHO, MUN, and MUO). The association of metabolic phenotypes with outcome was assessed using Cox regression models, adjusted for age, sex, and renal dysfunction. Within the total study cohort (median age 68 years, 57.3% male), 56.5% presented MH (43.3% MHN; 13.1% MHO) and 43.5% MU (28.3% MUN; 15.2% MUO). Irrespective of CCS, metabolic phenotypes showed different risks for MACE, all-cause mortality, and revascularization. While metabolic disease emerged as a robust predictor of events, obesity alone did not [e.g. in patients with obstructive CCS: MHO vs. MHN: adj. hazard ratio (HR) 0.947, 95% confidence interval (CI) 0.728-1.231, P = 0.683; MUO vs. MUN: adj. HR 0.974 (95% CI 0.809-1.172), P = 0.780]. However, MH individuals experienced lower event rates with increasing body mass index (BMI). CONCLUSION: This study indicates metabolic health, rather than obesity, is a key predictor of adverse events in CCS prevention, revealing an obesity paradox in MH individuals. Thus, cardiovascular risk assessment should prioritize metabolic health over BMI. Integrating metabolic profiling into routine evaluations may help optimize prevention and personalized treatment strategies.
No takes yet. Share an insight, caveat, or question.
Steinacher et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: